Reason for request

Amendment to the conditions for inclusion on the list of medicines approved for hospital use for Crohn’s disease in adults (extension of the indication to moderate forms).


Clinical Benefit


The actual benefit of this proprietary medicinal product is substantial.

Clinical Added Value

Comments without ASMR value

Data submitted within the context of the extension of the indication of REMICADE to moderate forms of Crohn's disease after failed treatment with corticosteroids is not sufficient enough to change the IAB level previously given for Crohn's disease.

Contact Us

Évaluation des médicaments

See also